Table 2.
Descriptive summary of HIV-related indicators for perinatally HIV-infected (PHIV+) youth (N = 196)
| Baseline N (%) | Follow-up 1 (FU2) N (%) | Follow-up 2 (FU2) N (%) | |
|---|---|---|---|
| Proportion virally suppresseda | 130 (66.3) | 128 (65.3) | 121 (61.7) |
| CD4 cell count (cells/mm3) | |||
| <500 | 79 (40.3) | 83 (51.2) | 91 (55.8) |
| 501–1000 | 91 (46.4) | 64 (39.5) | 56 (34.3) |
| >1000 | 26 (13.3) | 15 (9.3) | 16 (9.8) |
| Proportion on ART | 166 (86.0) | 133 (82.9) | 151 (91.0) |
| Type of ART regimenb | |||
| NNRTI | 40 (24.1) | 23 (11.7) | 42 (21.4) |
| PI | 101 (60.8) | 70 (35.7) | 98 (50.0) |
| NRTI | 160 (96.4) | 97 (49.5) | 135 (68.9) |
| Otherc | 3 (1.8) | 3 (1.5) | 27 (13.8) |
| Proportion of Efavirenzb | 21 (12.6) | 11 (8.3) | 23 (15.2) |
NRTI nucleoside reverse transcriptase inhibitor; P1 protease inhibitor; NNRTI Non-nucleoside reverse transcriptase inhibitor
a
Viral suppression defined as HIV viral load of less than 200 copies/mL [56]
b
Computed as proportion of respondents on ART
c
Other includes entry and fusion inhibitors, integrase inhibitors, CCR5 inhibitors